Clinical Features and Treatment of Dementia Associated With Parkinson’s Disease

  • Murat Emre
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Alzheimer Disease Parkinson Disease Multiple System Atrophy Dementia With Lewy Body Progressive Supranuclear Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK: the CamPaIGN study. Brain 2004;127:1–11.CrossRefGoogle Scholar
  2. 2.
    Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002;51:722–729.PubMedCrossRefGoogle Scholar
  3. 3.
    Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976;53:81–102.PubMedGoogle Scholar
  4. 4.
    Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538–542.PubMedGoogle Scholar
  5. 5.
    Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992;49:492–497.PubMedGoogle Scholar
  6. 6.
    Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730–736.PubMedGoogle Scholar
  7. 7.
    Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–392.PubMedCrossRefGoogle Scholar
  8. 8.
    Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229–237PubMedCrossRefGoogle Scholar
  9. 9.
    Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Cappa S (eds) Handbook of neuropsychology. 2nd ed. Elsevier Sciences, Amsterdam, 2001, pp 311–371.Google Scholar
  10. 10.
    Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091–2096.PubMedGoogle Scholar
  11. 11.
    Crucian GP, Okun MS. Visual-spatial ability in Parkinson's disease. Front Biosci 2003;8:992–997.CrossRefGoogle Scholar
  12. 12.
    Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:184–191.PubMedCrossRefGoogle Scholar
  13. 13.
    Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243–248.PubMedCrossRefGoogle Scholar
  14. 14.
    Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983;59:277–289.PubMedCrossRefGoogle Scholar
  15. 15.
    Dubois B, Ruberg M, Javoy-Agid F, et al. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 1983;288:213–218.PubMedCrossRefGoogle Scholar
  16. 16.
    Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413–421.PubMedCrossRefGoogle Scholar
  17. 17.
    Perry RH, Perry EK, Smith CJ, et al. Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. J Neural Transm Suppl 1987;24:131–136.PubMedGoogle Scholar
  18. 18.
    Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407–411.PubMedGoogle Scholar
  19. 19.
    Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745–1748.PubMedCrossRefGoogle Scholar
  20. 20.
    Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002;23:245–254.PubMedCrossRefGoogle Scholar
  21. 21.
    Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164–171PubMedCrossRefGoogle Scholar
  22. 22.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509–2518.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Murat Emre
    • 1
  1. 1.Professor of Neurology, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders UnitIstanbul University34390 ÇapaTurkey

Personalised recommendations